溶血磷脂酸在结直肠癌发生发展中的机制研究

doi:10.11904/j.issn.1002-3070.2020.03.017

摘要/Abstract

摘要： 近年来,自分泌运动因子-溶血磷脂酸(Autotaxin-lysophosphatidic acid,ATX-LPA)信号通路在结直肠癌发生发展中的重要性已逐渐得到了医学界的广泛认可。LPA信号可以通过至少6种G蛋白偶联受体(Gprotein-coupled receptors,GPCRs),即LPA_1-6,诱导各种细胞进程,包括伤口愈合、分化、增殖、迁移和存活等,这些细胞进程对维持肠上皮屏障的功能、促进结直肠癌细胞的存活、增殖及转移都十分重要。因此,本文对近年来发现的ATX-LPA信号通路与结直肠癌相关炎症的关系,及该信号通路对结直肠癌发生发展过程的影响进行综述,同时也对LPA及相关分子在结直肠癌治疗中的价值前景做出预测。

关键词: 溶血磷脂酸, 结直肠癌, 信号通路, 炎症, 治疗前景

Abstract: In recent years,the importance of autotaxin-lysophosphatidic acid(ATX-LPA)signaling pathway in the development of colorectal cancer has gradually been widely recognized by the medical community.LPA signals can induce various cellular processes including wound healing,differentiation,proliferation,migration,and survival through at least 6 G Protein-coupled receptors(GPCRs),that is,LPA_1-6.It is very important to maintain the function of intestinal epithelial barrier and promote the survival,proliferation and metastasis of colorectal cancer cells.Therefore,this article reviews the relationship between the ATX-LPA signaling pathway and colorectal cancer-related inflammation discovered in recent years,and the effect of colorectal cancer-related inflammation discovered in recent years,and the effect of this signaling pathway on the development of colorectal cancer.It also reviews LPA and related molecules in colorectal cancer treatment and predicting prospects.

Key words: Lysophosphatidic acid, Colorectal cancer, Signal pathway, Inflammation, Treatment prospects

中图分类号:

R735.3

鲁雪梅, 李云涛, 安锦慧, 季国忠. 溶血磷脂酸在结直肠癌发生发展中的机制研究[J]. 实用肿瘤学杂志, 2020, 34(3): 276-281.

LU Xuemei,LI Yuntao,AN Jinhui,JI Guozhong. The mechanism of lysophosphatidic acid in the development of colorectal cancer[J]. Journal of Practical Oncology, 2020, 34(3): 276-281.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2020.03.017

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2020/V34/I3/276

参考文献

1 Arnold M,Sierra MS,Laversanne M,et al.Global patterns and trends in colorectal cancer incidence and mortality[J].Gut,2017,66(4):683-691.
2 Zheng RS,Sun KX,Zhang SW,et al.Report of cancer epidemiology in China,2015[J].Zhonghua Zhong Liu Za Zhi,2019,41(1):19-28.
3 Peterson LW,Artis D.Intestinal epithelial cells:regulators of barrier function and immune homeostasis[J].Nat Rev Immunol,2014,14(3):141-153.
4 Balkwill F,Mantovani A.Inflammation and cancer:back to Virchow?[J].Lancet,2001,357(9255):539-545.
5 Kappelman MD,Farkas DK,Long MD,et al.Risk of cancer in patients with inflammatory bowel diseases:a nationwide population-based cohort study with 30 years of follow-up evaluation[J].Clin Gastroenterol Hepatol,2014,12(2):265-273.
6 Bottazzi B,Riboli E,Mantovani A.Aging,inflammation and cancer[J].Semin Immunol,2018,40:74-82.
7 Valdes-Rives SA,Gonzalez-Arenas A.Autotaxin-lysophosphatidic acid:from inflammation to cancer development[J].Mediators Inflamm,2017,2017:9173090.
8 Yun CC.Lysophosphatidic acid and autotaxin-associated effects on the initiation and progression of colorectal cancer[J].Cancers(Basel),2019,11(7):958.
9 Benesch MGK,Tang X,Venkatraman G,et al.Recent advances in targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis in vivo[J].J Biomed Res,2016,30(4):272-284.
10 Gonzalezgil I,Zian D,Vazquezvilla H,et al.The status of the lysophosphatidic acid receptor type 1(LPA1R)[J].Med Chem Comm,2015,6(1):13-23.
11 Taniguchi R,Inoue A,Sayama M,et al.Structural insights into ligand recognition by the lysophosphatidic acid receptor LPA6[J].Nature,2017,548(7667):356-360.
12 Chun J,Hla T,Lynch KR,et al.International union of basic and clinical pharmacology LXXVIII lysophospholipid receptor nomenclature[J].Pharmacol Rev,2010,62(4):579-587.
13 Imielinski M,Baldassano RN,Griffiths A,et al.Common variants at five new loci associated with early-onset inflammatory bowel disease[J].Nat Genet,2009,41(12):1335-1340.
14 Farooq SM,Hou Y,Li H,et al.Disruption of GPR35 exacerbates dextran sulfate sodium-induced colitis in mice[J].Dig Dis Sci,2018,63(11):2910-2922.
15 Wang L,Zhou W,Zhong Y,et al.Overexpression of G protein-coupled receptor GPR87 promotes pancreatic cancer aggressiveness and activates NF-kappaB signaling pathway[J].Mol Cancer,2017,16(1):61.
16 Choi JW,Herr DR,Noguchi K,et al.LPA receptors:subtypes and biological actions[J].Annu Rev Pharmacol Toxicol,2010,50:157-186.
17 Yun CC,Kumar A.Diverse roles of LPA signaling in the intestinal epithelium[J].Exp Cell Res,2015,333(2):201-207.
18 Colotta F,Allavena P,Sica A,et al.Cancer-related inflammation,the seventh hallmark of cancer:links to genetic instability[J].Carcinogenesis,2009,30(7):1073-1081.
19 Cai Y,Yousef A,Grandis JR,et al.NSAID therapy for PIK3CA-altered colorectal,breast,and head and neck cancer[J].Adv Biol Regul,2019,15:100653.
20 Tigyi GJ,Yue J,Norman DD,et al.Regulation of tumor cell -microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis[J].Adv Biol Regul,2019,71:183-193.
21 Kinzler KW,Vogelstein B.Lessons from hereditary colorectal cancer[J].Cell,1996,87(2):159-170.
22 Kazama S,Kitayama J,Aoki J,et al.Immunohistochemical detection of autotaxin(ATX)/lysophospholipase D(lysoPLD)in submucosal invasive colorectal cancer[J].J Gastrointest Cancer,2011,42(4):204-211.
23 Knowlden S,Georas SN.The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation[J].J Immunol,2014,192(3):851-857.
24 Yung YC,Stoddard NC,Chun J.LPA receptor signaling:pharmacology,physiology,and pathophysiology[J].J Lipid Res,2014,55(7):1192-1214.
25 Lin S,Wang D,Iyer S,et al.The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer[J].Gastroenterology,2009,136(5):1711-1720.
26 Lin S,Lee SJ,Shim H,et al.The absence of LPA receptor 2 reduces the tumorigenesis by ApcMin mutation in the intestine[J].Am J Physiol Gastrointest Liver Physiol,2010,299(5):1128-1138.
27 Guo L,He P,No YR,et al.Kruppel-like factor 5 incorporates into the beta-catenin/TCF complex in response to LPA in colon cancer cells[J].Cell Signal,2015,27(5):961-968.
28 Zhang H,Bialkowska A,Rusovici R,et al.Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of Kruppel-like factor 5[J].J Biol Chem,2007,282(21):15541-15549.
29 Li J,Xi W,Li X,et al.Advances in inhibition of protein-protein interactions targeting hypoxia-inducible factor-1 for cancer therapy[J].Bioorg Med Chem,2019,27(7):1145-1158.
30 Ha JH,Radhakrishnan R,Jayaraman M,et al.LPA induces metabolic reprogramming in ovariancancer via a pseudohypoxic response[J].Cancer Res,2018,78(8):1923-1934.
31 Lee SJ,No YR,Dang DT,et al.Regulation of hypoxia-inducible factor 1alpha(HIF-1alpha)by lysophosphatidic acid is dependent on interplay between p53 and kruppel-like factor 5[J].J Biol Chem,2013,288(35):25244-25253.
32 Ha JH,Ward JD,Radhakrishnan R,et al.Lysophosphatidic acid stimulates epithelial to mesenchymal transition markerslug/snail2 in ovarian cancer cells via Galphai2,Src,and HIF1alpha signaling nexus[J].Oncotarget,2016,7(25):37664-37679.
33 De Craene B,Berx G.Regulatory networks defining EMT during cancer initiation and progression[J].Nat Rev Cancer,2013,13(2):97-110.
34 Benesch MGK,Ko YM,Tang X,et al.Autotaxin is an inflammatory mediator and therapeutic target in thyroid cancer[J].Endocr Relat Cancer,2015,22(4):593-607.
35 Radhakrishnan R,Ha JH,Jayaraman M,et al.Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts[J].Cancer Lett,2019,442:464-474.
36 Seo EJ,Kwon YW,Jang IH,et al.Autotaxin regulates maintenance of ovarian cancer stem cells through lysophosphatidic acid-mediated autocrine mechanism[J].Stem Cells,2016,34(3):551-564.
37 Brindley DN,Lin F,Tigyi G.Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy[J].Biochim Biophys Acta,2013,1831(1):74-85.
38 Li Y,Zhang W,Zhang J,et al.Plasma levels of lysophosphatidic acid in ovarian cancer versus controls:a meta-analysis[J].Lipids in Health & Disease,2015,14(1):72.
39 Benesch MG,Tang X,Venkatraman G,et al.Recent advances in targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis in vivo[J].J Biomed Res,2016,30(4):272-284.
40 Venkatraman G,Benesch MG,Tang X,et al.Lysophosphatidate signaling stabilizes Nrf2 and increases the expression of genes involved in drug resistance and oxidative stress responses:implications for cancer treatment[J].Faseb J,2015,29(3):772-785.
41 Miyabe C,Miyabe Y,Nagai J,et al.Abrogation of lysophosphatidic acid receptor 1 ameliorates murine vasculitis[J].Arthritis Res Ther,2019,21(1):191.
42 Knowlden SA,Hillman SE,Chapman TJ,et al.Novel inhibitory effect of a lysophosphatidic acid 2 agonist on allergen-driven airway inflammation[J].Am J Respir Cell Mol Biol,2016,54(3):402-409.
43 Marshall JC,Collins JW,Nakayama J,et al.Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer[J].J Natl Cancer Inst,2012,104(17):1306-1319.
44 Ohashi T,Yamamoto T.Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin[J].Exp Dermatol,2015,24(9):698-702.
45 Nikitopoulou I,Kaffe E,Sevastou I,et al.A metabolically-stabilized phosphonate analog of lysophosphatidic acid attenuates collagen-induced arthritis[J].PLoS One,2013,8(7):e70941.
46 Zhang H,Xu X,Gajewiak J,et al.Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo[J].Cancer Res,2009,69(13):5441-5449.
47 Schleicher SM,Thotala DK,Linkous AG,et al.Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature[J].PLoS One,2011,6(7):e22182.
48 Benesch MG,Tang X,Dewald J,et al.Tumor-induced inflammation in mammary adipose tissue stimulates a vicious cycle of autotaxin expression and breast cancer progression[J].Faseb J,2015,29(9):3990-4000.
49 Leblanc R,Lee SC,David M,et al.Interaction of platelet-derived autotaxin with tumor integrin alphaVbeta3 controls metastasis of breast cancer cells to bone[J].Blood,2014,124(20):3141-3150.

[1]	朱晓云, 张亚宁, 马碧萍. 1980—2018年上海市金山区结直肠癌死亡水平及其所致早死概率的趋势分析[J]. 实用肿瘤学杂志, 2020, 34(3): 198-202.
[2]	曹宁, 夏百荣, 娄阁. HPV蛋白、miRNAs和外泌体在宫颈癌炎症作用中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 282-285.
[3]	王飞, 朱贲贲. 丙泊酚经HIF-1α信号通路对头颈鳞状细胞癌SCC-74细胞增殖、凋亡与侵袭的影响[J]. 实用肿瘤学杂志, 2020, 34(2): 120-125.
[4]	王璞, 韦丽宾, 倪广晓. CCNB1基因通过调控PI3K/Akt信号通路对口腔鳞癌细胞增殖、侵袭和迁移的影响[J]. 实用肿瘤学杂志, 2020, 34(2): 144-149.
[5]	李斌, 冯保恒, 尹富霞, 苏伟. 建立结直肠癌移植瘤模型研究小鼠肠道中细菌感染情况及地西他滨联合顺铂化疗的作用机制[J]. 实用肿瘤学杂志, 2020, 34(2): 163-168.
[6]	曾理, 庄树彤, 丁世华, 陈冲, 焦璐, 孙大勇. 长链非编码RNA AFAP1-AS1通过PTEN/p-AKT信号通路调控结直肠癌细胞增殖的分子机制研究[J]. 实用肿瘤学杂志, 2020, 34(1): 11-16.
[7]	廖代祥, 郑博, 张彦斌, 于军辉. RRBP1与RABEX-5蛋白在结直肠癌组织中的表达及与临床病理特征和预后的关系[J]. 实用肿瘤学杂志, 2020, 34(1): 43-48.
[8]	张景岚, 刘瑞宝. 结直肠癌肝转移瘤局部介入治疗应用进展[J]. 实用肿瘤学杂志, 2020, 34(1): 79-82.
[9]	李智杰, 赵琦, 吴华星. 通过宏基因组学研究肠道微生物对结直肠癌患者影响的最新进展[J]. 实用肿瘤学杂志, 2020, 34(1): 93-96.
[10]	曹舒, 李莎莎, 杨丹. 信号通路相关的microRNA在骨肉瘤中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(6): 544-548.
[11]	夏天一, 张博淼, 姚克非, 崔滨滨. PTPN9表达水平与结直肠癌的临床关系研究[J]. 实用肿瘤学杂志, 2019, 33(5): 415-419.
[12]	方瑄, 陈洪生, 李国东刘明. 异常隐窝灶治疗的研究进展[J]. 实用肿瘤学杂志, 2019, 33(4): 376-379.
[13]	方琳, 刘超, 张纯慧, 张艳桥. 转移性结直肠癌维持治疗的研究现状与治疗策略[J]. 实用肿瘤学杂志, 2019, 33(2): 173-178.
[14]	佟广海, 田洋, 吴华星. 脂质组学在结直肠癌研究中的应用[J]. 实用肿瘤学杂志, 2019, 33(2): 179-192.
[15]	刘恒辰, 张新宇. Toll样受体信号通路作为结直肠癌潜在治疗靶点的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 188-192.